Stock · Healthcare
GILD Gilead Sciences Inc.
Gilead Sciences Inc. scores well across yield, structure, and size — a typical strong-safety profile.
Why we rate it 8.8
- Yield of 2.57% is in the typical sustainable zone (2-4%)
- Payout ratio of 47% is comfortable — typical for mature dividend payers
- Current yield is below the 5-year average (3.69%), often a sign that price has appreciated faster than dividend growth
- Large-cap scale (>$50B) — established business with predictable cash flows
Where GILD ranks
We compute the same 0–10 safety score across 53 dividend-paying stocks and ETFs. Here's where GILD lands inside that universe.
The universe is curated to the most-searched US dividend payers. We'll expand it as the data layer grows; sector percentiles only appear when we have at least 5 comparable peers.
The two questions a safety score doesn't answer
A safety score tells you how durable GILD's payout looks. It does not tell you what you keep after tax, or whether something else does the same job better.
On tax: what you actually pocket depends on whether GILD dividends are qualified — qualified distributions are taxed at 0%, 15%, or 20%, while ordinary ones are taxed at your full marginal rate, a gap that can reach 22 percentage points of the income on the same headline yield.
On substitutes: if GILD's 8.8/10 score is lower than you want, see GILD alternatives — same-sector stocks ranked by how closely they match GILD on both yield and safety, so you can see what a swap actually costs you.
About Gilead Sciences Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
How we score dividend safety
The Infnits dividend safety score is a 0–10 rating derived from yield zone, payout ratio (when applicable), yield trend versus 5-year average, instrument type, and company size. Each factor is independently transparent — see the reasons above for exactly which factors contributed to GILD's score.
For the full methodology including the in-app version that uses ETF look-through and historical cut data, see our methodology page.
This is educational, not investment advice. Dividend safety scores reflect a snapshot of public data on the "as of" date shown. Verify current data on the issuer's investor relations page or your brokerage before making decisions.
Frequently asked questions
Is GILD safe?
On dividend safety specifically, Infnits scores GILD 8.8/10 — strong. Gilead Sciences Inc. scores well across yield, structure, and size — a typical strong-safety profile. That score measures how durable the payout looks based on yield zone, payout ratio, yield trend, and instrument type; it does not measure price risk, valuation, or whether GILD suits your portfolio.
Is GILD's dividend safe?
Based on snapshot data — yield 2.57%, payout ratio 47%, instrument type stock — Infnits rates GILD's dividend safety profile as strong (8.8/10). This is one signal, not a recommendation.
What is GILD's current dividend yield?
GILD has a current dividend yield of 2.57% as of April 28, 2026. Its 5-year average yield is 3.69%.
How is GILD's safety score calculated?
The score combines yield zone (yields above 7% historically carry elevated cut risk), payout ratio (lower is safer), trend vs. 5-year average yield, instrument type (ETFs are inherently more diversified), and size (larger companies have more stable cash flows). Each factor is scored 0-2.5 and summed to a 0-10 result.
Where does this data come from?
Fundamentals are sourced from public market data and refreshed regularly. The "as of" date on each page reflects the snapshot used for the score. For real-time data, check the issuer's investor relations page or your brokerage.
Should I buy GILD based on this score?
No — this is an educational score based on a handful of public signals, not investment advice. Use it as one input among many. For a portfolio-aware analysis with ETF look-through and personalized insights, install the Infnits app.
Get emailed when GILD score changes.
GILD head-to-head comparisons
See GILD compared side-by-side with the most-searched peer tickers — yield, safety, growth trend, expense ratio, and tax treatment.
More GILD analysis
Other dividend tickers
See how GILD fits your portfolio
Add your other holdings and the free analyzer shows your total annual income, weighted safety score, and whether GILD is carrying too much of your income. Runs in your browser — no account, no download.
Or read how safety scoring works.